The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review

Dec 15, 2020Expert review of pharmacoeconomics & outcomes research

Cost-effectiveness of weekly semaglutide compared to other similar diabetes drugs for type 2 diabetes

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Nineteen studies evaluating the cost-effectiveness of once-weekly semaglutide for type 2 diabetes treatment were systematically reviewed.

Eight short-term and eleven long-term studies were identified in the review.
The economic value of once-weekly semaglutide was compared with other GLP-1 receptor agonists.
Current studies may underestimate the cardiovascular benefits of once-weekly semaglutide.
The findings provide a basis for healthcare decision-making regarding once-weekly semaglutide in different countries.
Improvements in the methods of economic evaluations for new anti-diabetic drugs with cardiovascular benefits are suggested.

AI simplified

: As a novel glucagon-like peptide-1receptor agonist (GLP-1 RA) for type 2 diabetes (T2D) treatment, the economic value of once-weekly semaglutide had been assessed in several country settings. The authors' objective was to systematically review the existing pharmacoeconomic literature evaluating the cost-effectiveness associated with once-weekly semaglutide compared with other GLP-1 RAs and provide implications for further researches.: We conducted a systematic literature review of cost-effectiveness analysis (CEA) published up to 25 July 2020 in PubMed, web of science, and the ISPOR presentation database, compared once-weekly semaglutide with other GLP-1 RAs in T2D. Nineteen studies were identified, including 8 short-term and 11 long-term studies. General characteristics and main results of the included studies were summarized.: This review provided references for other countries to overview the value of once-weekly semaglutide compared with other GLP-1 RAs in T2D in the healthcare decision-making process and to conduct their CEA studies associated with once-weekly semaglutide. The authors found that the cardiovascular (CV) benefit of once-weekly semaglutide was under-estimated in current studies and suggested that the methods of economic evaluations for novel anti-diabetic drugs with CV benefit should be improved in future researches. Introduction Areas covered Expert opinion

Full Text

Full text is available at the source.

View full text ↗

The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief